AI Science Tracker

University of Pittsburgh School of Pharmacy

1 discovery from 2024

Discoveries

AI-guided HuJ3 mutation improves HIV-1 gp120 binding and neutralization in assays

The IsAb2.0 workflow, combining AlphaFold-Multimer complex modeling with FlexddG mutation scoring, proposed five substitutions to improve the binding of humanized J3 nanobody HuJ3 to HIV-1 gp120. Of these, E44R experimentally improved binding (ELISA EC50 1.696 nM) and neutralization relative to HuJ3; the other proposed substitutions did not consistently improve binding, and T99R failed to express. The gain did not restore neutralization to the parental llama J3 level.

Technology: IsAb2.0 antibody-design protocol integrating AlphaFold-Multimer 2.3/3.0, SnugDock, alanine scanning and FlexddG

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Of these, E44R experimentally improved binding (ELISA EC50 1.696 nM) and neutralization relative to HuJ3; the other proposed substitutions did not consistently improve binding, and T99R failed to express.
  • Still unknown: This is a single, previously known J3 nanobody humanization/optimization case, not de novo antibody discovery, animal efficacy or clinical evidence. Only one of five proposed mutants improved binding; several predictions failed and the authors note limitations in prediction accuracy and manual steps. E44R remained less potent than parental J3.
  • AI role: The protocol modeled the HuJ3–gp120 complex, nominated interface hotspots and computationally ranked five single-residue mutations. Researchers synthesized/tested variants in binding and HIV-1 neutralization assays; the measured E44R improvement is the experimental outcome, while most predictions did not improve performance.

Evidence sources: https://academic.oup.com/bib/article/25/5/bbae445/7758758

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 81 of works of the same type, year and subfield (OpenAlex work metrics, 11 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.